CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

CADTH Board of Directors Names Suzanne McGurn as Next President and CEO

May 19, 2020
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020. Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...

Patient Input and Clinical Experts: etonogestrel

May 6, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name TBC Generic name etonogestrel Manufacturer Merck Canada Inc. Indication(s) Prevention of pregnancy Project Number SR0648-000 Call for patient input 2020-05-06 Patient input deadlin...

COVID-19 Update Regarding Scientific Advice

May 6, 2020
In light of the COVID-19 pandemic, we’ve made some changes to our CADTH Scientific Advice Program activities. During this challenging and uncertain time, we recognize that clinical experts may not be available to participate in our projects. As input from Canadian clinical experts is key to producing high-quality and relevant advice, we’ve decid...

Patient Input and Clinical Experts: Entyvio

May 5, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Entyvio Generic name vedolizumab Manufacturer Takeda Canada Inc. Indication(s) Crohn’s disease Project Number SR0647-000 Call for patient input 2020-05-05 Patient input deadline ...